Associated Papers
Distinct Genetically Determined Origins of Myd88/BCL2-Driven Aggressive Lymphoma Rationalize Targeted Therapeutic Intervention Strategies.
Flümann R et al.
Blood Cancer Discovery, 2023
36346827 (PubMed )
Supplement: bcd-22-0007_table_s6_suppst6.xlsx › C_Mut_Pat.__2
Multidimensional Molecular Profiling of Metastatic Triple-Negative Breast Cancer and Immune Checkpoint Inhibitor Benefit.
Barroso-Sousa R et al.
Jco Precision Oncology, 2022
35797509 (PubMed )
Supplement: DS.PO.21.00413.xlsx › Supp_Table_S2
In vivo anti-tumor effect of PARP inhibition in IDH1/2 mutant MDS/AML resistant to targeted inhibitors of mutant IDH1/2.
Gbyli R et al.
Leukemia, 2022
35273342 (PubMed )
Supplement: NIHMS1782098-supplement-Supplemental_material.pdf
Select a paper to view details